DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.
Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.
Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.
Gwénola Tanneau
Founder and CEO, DIAGOMICS
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth, as well as investing in service quality, innovation and efficiency.
Learn moreGroupe JVS has completed an LBO with Capza and Bpifrance
The shareholders of Groupe JVS have completed an LBO with Capza and BpiFrance. Parquest sold their shares after partnering with the organization for three years. Groupe JVS’s management team will increase its ownership and remain as the majority shareholder of the group, alongside CAPZA and Bpifrance.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn more